Fluvoxamine is recommended as first‐line treatment for a number of obsessive–compulsive disorders, anxiety disorders, social phobia, and post‐traumatic stress disorder and panic disorder. The adverse effects of prolonged oral administration of fluvoxamine on haematology, biochemical parameters and fertility in male rats were evaluated in this study. Sixty adult male rats were allocated into 5 equal groups and orally treated with fluvoxamine 9mg kg?1 b.wt. (low therapeutic dose, LTD) and 27mg kg?1 b.wt. (high therapeutic dose, HTD), while the control rats received 0.5 ml distilled water for a period of 8 weeks. The 4th and 5th groups were gavaged with LTD and HTD of fluvoxamine for 8 weeks and then left untreated for another 8 weeks (recovery groups). HTD of fluvoxamine induced leukocytosis, lymphocytosis and monocytosis. LTD and HTD of fluvoxamine evoked hepatic, renal and cardiac dysfunction. Moreover, fluvoxamine treatment might lead to the risk of male infertility, which is indicated by its deleterious impacts on spermiogram and steroidogenesis hormones. They also induced oxidative stress, apoptosis in testicular tissue. Fortunately, the previous alterations were mostly reversed during the recovery period. 相似文献
Introduction: Panic disorder (PD) is a prevalent and disabling anxiety disorder that can be treated effectively. Selective serotonin reuptake inhibitors (SSRIs) and benzodiazepines are among the most frequently prescribed drugs for PD. In this article, the authors review the current evidence on efficacy, adverse events, and limitations of these two treatment options.
Areas covered: MEDLINE/Pubmed and Web of Science databases were searched for open or placebo-controlled trials on SSRIs and/or benzodiazepines in PD treatment.
Expert opinion: The literature search yielded 4,957 articles related to the theme. Of these, 24 articles were included in this review. Despite their usefulness in PD, SSRIs are associated with a delay of several weeks in onset of therapeutic effect and have the potential to exacerbate anxiety and panic early in the treatment course. Benzodiazepines present rapid onset of action, but can cause tolerance and dependence. Despite strong evidence of the effectiveness of SSRIs and benzodiazepines in the treatment of PD, few trials have performed head-to-head comparisons of these two drug classes. Future studies on the pharmacological treatment of PD should make direct comparisons of risks, benefits, and limitations of each group. This could help improve the evidence-based pharmacotherapy of PD. 相似文献
SYNOPSIS Forty out-patients affected by chronic tension-type headache were selected according to the diagnostic criteria of International Headache Society (IHS) Headache Classification Committee. In a controlled trial patients received placebo for a four-week baseline period, then they were randomized in double-blind fashion to therapy with mianserine (30-60 mg/day) or fluvoxamine (50-100 mg/day) for another eight-week period. Frequency of headache, pain severity and analgesic consumption were evaluated using a self-monitoring system. Mood depression was evaluated at 0, 4 and 8 weeks by using Zung'ss Self-Rating Depression Scale and Hamilton Rating Scale for Depression. Both drugs were beneficial in the treatment of chronic tension-type headache. Non-depressed subjects with more severe headache responded best to fluvoxamine, whereas mianserine was more effective in the treatment of depressed patients with moderate headache. These results suggest that central serotoninergic neurotransmission can play a role in the pathophysiology of chronic tension-type headache also in non-depressed patients. 相似文献
Objective: To observe treatment effects and safety of fluvoxamine combined with oxycodone prolonged-releasetablets in treating patients with moderate to severe cancer pain. Methods: Patients confirmed pathologicallywith cancer and complicated with moderate to severe pain, were divided into control and experimental groups.Oxycodone prolonged-release tablets, with or without fluvoxamine, were administrated to all study patientsuntil pain relief. Degree of pain relief, dose of oxycodone prolonged-release tablets, side effects and quality oflife were compared before and after treatment. Results: In total, 120 patients were recruited. No statisticallysignificant difference was detected regarding age, gender, types of cancer, KPS between two groups of patients(P> 0.05). Baseline pain score of patients with moderate pain in treatment and control group was 4.9±0.8 and5.1±0.8, respectively; and decreased to 1.8±1.1 and 1.2±1.1 after treatment, respectively. Pain intensity wassignificantly reduced in the treatment group (P =0.028). Average daily consumption of oxycodone prolongedreleasetablets was (54.0±19.6) mg and (44.7± 18.7) mg respectively, which is lower in treatment grpup than incontrol group, but the difference was not statistically significant (P=0.065). Baseline pain score of patients withsevere pain in treatment and control groups were 8.3±1.1 and 8.3±1.1, respectively; and pain intensity aftertreatment decreased to 2.9±1.0 and 2.3±1.0. Pain intensity was significantly reduced in the treatment group,with statistical significance (P =0.026). Average daily consumption of oxycodone prolonged-release tablets was(132.0±42.2) mg and (110.7±33.9) mg, respectively, which is lower in treatment group than in control group, andthe difference was statistically significant (P=0.035). In terms of quality of life, patients in treatment group hadbetter performance status, daily activity, mood, and sleep than that in control group (P < 0.05). Patients in twogroups had similar side effects, eg., constipation, nausea/vomiting, lethargy, dizziness, itchy skin, dysuria, andataxia. Lower incidence of nausea/vomiting, lethargy, was obtained from patients in treatment than in controlgroup, while significant low constipation was observed in treatment than in control group (35.0% vs 49.2%,P=0.026). Conclusion: Fluvoxamine combined with oxycodone prolonged-release tablets could be more effectivein treating patients with cancer pain, and could reduce the dosage of oxycodone prolonged-release tablets andthus be associated with lower side effects, and improved quality of life. 相似文献